LINOZOL 600

LINOZOL 600 contains Linezolid IP 600 mg, a synthetic antibiotic belonging to the oxazolidinone class, designed to combat serious bacterial infections. It works by inhibiting bacterial protein synthesis, making it highly effective against Gram-positive bacteria, including strains resistant to other antibiotics such as MRSA (Methicillin-resistant Staphylococcus aureus) and VRE (Vancomycin-resistant Enterococcus).

Key Benefits:

• Broad-spectrum activity against resistant Gram-positive infections
  ● Effective for treating infections caused by MRSA and VRE
  ● Excellent tissue penetration for systemic infections
  ● Available in oral and injectable forms for flexible treatment
  ● Suitable for both hospital and community-acquired infections
• Indications:

• Treatment of nosocomial pneumonia and community-acquired pneumonia
  ● Skin and soft tissue infections, including complicated cases
  ● Infections caused by MRSA and VRE
  ● Other serious Gram-positive bacterial infections resistant to conventional therapy